메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity

- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 in 65 participants with obesity or overweight. - The ultra-long-acting SQ depot treatment formulation of small molecule ASC30 demonstrated a 46-day observed half-life in participants with obesity in the Phase Ib study, supporting once-monthly administration. - Topline data from the 12-week Phase IIa study of ASC30 once-monthly SQ depo
- 김갑성 기자
- 2025-10-20 08:10
ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

SUZHOU, China, Oct. 20, 2025 -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced the first disclosure of preliminary Phase I data for CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody) and the Phase Ib study design for CS5001 (a ROR1-targeted Antibody-Drug Conjugate [ADC]) at the 2025 European Society for Medical Oncology (ESMO) Annual Congress. Key Highlights of CS2009 Poster Presentation:
- 김갑성 기자
- 2025-10-20 08:10
Leading Competition Economist Dr. Luke Wainscoat Joins The Brattle Group

SYDNEY, Oct. 20, 2025 -- The Brattle Group has welcomed Dr. Luke Wainscoat to its growing Sydney office as a Principal in the firm's Antitrust & Competition practice. An economist with 20 years of experience, Dr. Wainscoat advises clients on complex competition, regulatory, and damages matters in Australia and New Zealand. Recognized as one of Australia's top competition economists by Lexology Index (previously Who's Who Legal), Dr. Wainscoat's expertise includes merger clearance processes, cartel investigations, anticompetitive agreements, and misuses of market power. He h
- 황정호 기자
- 2025-10-20 07:25
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances

SHANGHAI, Oct. 20, 2025 -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced the appointment of Nicholas Jackson, Ph.D., as President of Global R&D and Alliances. Dr. Jackson will work closely with the Company's CEO, Joshua Liang, to accelerate the development of Clover's RSV+hMPV±PIV3 combination vaccine candidates and lead potential alliances with global collaborators. "We are excited to welcom
- 김갑성 기자
- 2025-10-20 07:00
Webull Reduces Minimum ASX Trading Fee To $1

Webull Australia now offers the lowest-cost CHESS-sponsored brokerage fee minimums for trading ASX shares The new pricing structure is paired with Webull's industry-leading technology and free live pricing data $1.00 minimum fees will be made available to Australian clients from 20 October 2025 SYDNEY, Oct. 20, 2025 -- Webull Securities (Australia) Pty Ltd ('Webull Australia'), a subsidiary of Webull Corporation (NASDAQ: BULL), has today reduced ASX trading fees for CHESS-sponsored stocks to a minimum of $1.00, or 3-basis points. Australian and US ETF trades on the pla
- 황정호 기자
- 2025-10-20 06:00
Yaber Expands Its Global Footprint -- Now Available at JB Hi-Fi Across Australia

SYDNEY, Oct. 20, 2025 -- Yaber, a pioneer of entertainment projectors, now announces its official entry into JB Hi-Fi, one of Australia's largest home entertainment retailers. This marks another milestone in Yaber's global expansion, bringing its award-winning projectors to more homes and families across Australia and strengthening the brand's growing presence throughout the Asia-Pacific region. Starting today, Yaber's best-selling models are available both online and in-store at JB Hi-Fi locations nationwide. Whether it's a high-end laser projector or a portable model,
- 김장윤(JASON KIM) 기자
- 2025-10-20 05:00
Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025

HONG KONG, Oct. 19, 2025 -- On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) . COMPASSION-15 is a Phase III clinical trial evaluating cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with oxaliplatin and capecitabine as first-line treatment for unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. Professor Shen Lin, principal investigator from Peking University
- 김갑성 기자
- 2025-10-19 23:42
HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet

[ 메디채널 김갑성 기자 ] Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001. The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24 months), indicating significantly prolonged progression-free survival with ivonescimab combination therapy. Significant benefits were consistently observed with ivonescimab plus chemotherapy versus tislelizumab combination irrespective of PD-L1 expression. Ivonescimab combination therapy showed significant benefit over tislelizumab regimen in patients with or without liver metastase
- 김갑성 기자
- 2025-10-19 23:37
United Imaging Marks Five Years Since the Opening of its Global Showroom In North America with a Record Number of U.S. Customer Visits

[ 메디채널 김갑성 기자 ] The company launched American R&D in 2013 and American commercial operations in 2018; in 2020 it opened a 100,000 square foot production and training center in Houston, and just tripled its local footprint to support strong growth. HOUSTON, Oct. 19, 2025 -- United Imaging, a global manufacturer of modern medical imaging technology, saw a record number of visits to its North American hub from U.S. healthcare providers in one week in October, and an overall spike in 2025. The nearly 100,000 square foot facility first opened its doors in Houston in 2020, and
- 김갑성 기자
- 2025-10-19 22:00
Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting

[ 메디채널 김갑성 기자 ] AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in heavily pretreated patients with melanoma and gynecologic cancers without MUC18 preselection SHANGHAI, Oct. 19, 2025 -- Multitude Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of ADC drugs, today announced interim results from its ongoing Phase I/II open-label, multicente
- 김갑성 기자
- 2025-10-19 15:00

이전

41 42 43 44 45 46 47 48 49 50

많이 본 기사

최근기사

2025-10-29_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 29일 19시 40분